Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilka Isfort

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Molecular Cancer Research : MCR|March 15, 2023
Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial SarcomaIlka Isfort, Ruth Berthold, Lorena Heinst, et al.
Cells|December 24, 2025
SS18::SSX and BRD9 Modulate Synovial Sarcoma DifferentiationAnna Kuntze, Victor Banerjee, Marcel Trautmann, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 2, 2021
Recurrent CTNNB1 mutations in craniofacial osteomasDaniel Baumhoer, Ruth Berthold, Ilka Isfort, et al.
Oncogenesis|April 23, 2022
Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcomaRuth Berthold, Ilka Isfort, Cihan Erkut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2024
Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid LiposarcomaLorena Heinst, Kwang Seok Lee, Ruth Berthold, et al.
Molecular Cancer Therapeutics|February 22, 2019
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid LiposarcomaMarcel Trautmann, Magdalene Cyra, Ilka Isfort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2017
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid LiposarcomaMarcel Trautmann, Jasmin Menzel, Christian Bertling, et al.
Cellular Oncology (Dordrecht, Netherlands)|May 13, 2022
SS18-SSX drives CREB activation in synovial sarcomaMagdalene Cyra, Miriam Schulte, Ruth Berthold, et al.
Scientific Reports|December 25, 2019
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and BoneIlka Isfort, Sandra Elges, Magdalene Cyra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2019
SS18-SSX-Dependent YAP/TAZ Signaling in Synovial SarcomaIlka Isfort, Magdalene Cyra, Sandra Elges, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Molecular Cancer Research : MCR|March 15, 2023
Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial SarcomaIlka Isfort, Ruth Berthold, Lorena Heinst, et al.
Cells|December 24, 2025
SS18::SSX and BRD9 Modulate Synovial Sarcoma DifferentiationAnna Kuntze, Victor Banerjee, Marcel Trautmann, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 2, 2021
Recurrent CTNNB1 mutations in craniofacial osteomasDaniel Baumhoer, Ruth Berthold, Ilka Isfort, et al.
Oncogenesis|April 23, 2022
Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcomaRuth Berthold, Ilka Isfort, Cihan Erkut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2024
Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid LiposarcomaLorena Heinst, Kwang Seok Lee, Ruth Berthold, et al.
Molecular Cancer Therapeutics|February 22, 2019
Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid LiposarcomaMarcel Trautmann, Magdalene Cyra, Ilka Isfort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2017
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid LiposarcomaMarcel Trautmann, Jasmin Menzel, Christian Bertling, et al.
Cellular Oncology (Dordrecht, Netherlands)|May 13, 2022
SS18-SSX drives CREB activation in synovial sarcomaMagdalene Cyra, Miriam Schulte, Ruth Berthold, et al.
Scientific Reports|December 25, 2019
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and BoneIlka Isfort, Sandra Elges, Magdalene Cyra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2019
SS18-SSX-Dependent YAP/TAZ Signaling in Synovial SarcomaIlka Isfort, Magdalene Cyra, Sandra Elges, et al.
Pageof 2